January 24, 2017 / 1:13 PM / in a year

BRIEF-Celgene Inc says Health Canada has expanded indication for REVLIMID in multiple myeloma

Jan 24 (Reuters) - Celgene Corp

* Celgene Inc says Health Canada has expanded indication for REVLIMID in multiple myeloma

* Celgene Corp says REVLIMID in combination with dexamethasone, is indicated for treatment of multiple myeloma patients who are not eligible for stem cell transplant Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below